The twiist insulin pump is now compatible with the Eversense 365 one-year implantable continuous glucose monitor (CGM), with the first commercial users already up and running. This makes twiist the first automated insulin delivery (AID) system to integrate with Eversense 365. It also builds on twiist’s earlier launch with Libre 3 Plus, reinforcing its focus on user’s choice.

For people who have want to combine an implantable CGM with a modern AID system, this integration represents a meaningful shift. Eversense 365 offers up to a full year of glucose sensing from a single implanted sensor, reducing the ongoing cycle of sensor insertions required by traditional CGMs. A removable, rechargeable transmitter sits above the skin and sends glucose data every five minutes to a smartphone and provides on body vibration alerts for highs and lows. With Eversense 365 now cleared as an interoperable CGM (iCGM), it can officially connect with systems like twiist.

On the pump side, twiist brings several unique technical features. It is a tubed insulin pump that directly measures the actual volume of insulin delivered with each microdose using sound waves, providing real time confirmation of delivery. Users can control the system from an iPhone and Apple Watch. twiist also offers one of the lowest glucose targets available in the US at 87 mg per dL (4.83 mmol/L), along with advanced occlusion detection. We have spoken with early twiist users, and produced videos showcasing a twiist site change and app walkthrough. Our product review is coming soon.

Together, twiist and Eversense 365 introduce a new level of personalization in diabetes technology. By supporting multiple CGMs and offering a one year implantable sensor option, this combination gives users flexibility. Leave a comment below with your thoughts on this integration!

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.